ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

FDA News: FDA Grants Accelerated Approval to Mekinist-Tafinlar Combination

January 10, 2014

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

January 27, 1989

NCI-Approved Clinical Trials

July 28, 2006

Kimmel Donates $150 Million To Hopkins For Cancer Research, Patient Residence.

November 16, 2001

Congressional Report Says NCI Ignored Das, Procedure, In Charges To Screening Guidelines

November 4, 1994

Waxman To Speak At AACI Meeting

January 12, 1979